{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,24]],"date-time":"2025-12-24T06:31:10Z","timestamp":1766557870999,"version":"3.41.2"},"reference-count":32,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2021,12,14]],"date-time":"2021-12-14T00:00:00Z","timestamp":1639440000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Pharmacol."],"abstract":"<jats:p><jats:bold>Aim:<\/jats:bold> To investigate the incidence of, and factors associated with addition and switching of glucose-lowering medications within 12-months of initiating metformin or a sulfonylurea for type 2 diabetes (T2D).<\/jats:p><jats:p><jats:bold>Methods:<\/jats:bold> We identified 109,573 individuals aged 18\u201399\u00a0years who initiated metformin or a sulfonylurea between July 2013 and April 2015 using Australian National Diabetes Service Scheme (NDSS) data linked with national dispensing data. Cox proportional hazards regression was used to estimate adjusted hazard ratios (HRs) with 95% confidence intervals (CI) for factors associated with time to addition to or switch from metformin or sulfonylurea over a 12-months follow-up.<\/jats:p><jats:p><jats:bold>Results:<\/jats:bold> Treatment addition or switching occurred in 18% and 4% of individuals who initiated metformin and in 28% and 13% of individuals who initiated sulfonylureas. Median time to addition was 104\u00a0days for metformin and 82\u00a0days for sulfonylureas. Median time to switching was 63\u00a0days for metformin and 52\u00a0days for sulfonylureas. Congestive heart failure, nicotine dependence, end stage renal disease and dispensing of systemic corticosteroids were associated with higher likelihood of treatment additions and switching in individuals initiating metformin. Antipsychotic dispensing was associated with a higher likelihood of treatment addition in individuals initiating sulfonylureas. Women initiating metformin were less likely to receive treatment additions but more likely to switch treatment than men.<\/jats:p><jats:p><jats:bold>Conclusion:<\/jats:bold> Nearly one quarter of Australians who initiate treatment for T2D with metformin or sulfonylureas switch or receive additional treatment within 12-months, with those who initiate sulfonylureas more likely to switch or receive additional treatment than those who initiate metformin.<\/jats:p>","DOI":"10.3389\/fphar.2021.794273","type":"journal-article","created":{"date-parts":[[2021,12,14]],"date-time":"2021-12-14T12:05:40Z","timestamp":1639483540000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":4,"title":["Treatment Dynamics in People Who Initiate Metformin or Sulfonylureas for Type 2 Diabetes: A National Cohort Study"],"prefix":"10.3389","volume":"12","author":[{"given":"Stephen","family":"Wood","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dianna J.","family":"Magliano","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J Simon","family":"Bell","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jonathan E.","family":"Shaw","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jenni","family":"Ilom\u00e4ki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2021,12,14]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"1979","DOI":"10.2337\/dc20-ad08a","article-title":"Addendum. 9. Pharmacologic Approaches to Glycemic Treatment: Standards of Medical Care in Diabetes-2020. Diabetes Care 2020;43(Suppl. 1):S98-S110","volume":"43","year":"2020","journal-title":"Diabetes Care"},{"key":"B2","doi-asserted-by":"crossref","first-page":"119","DOI":"10.2337\/dc18-S011","article-title":"Older Adults: Standards of Medical Care in Diabetes","volume":"41","year":"2018","journal-title":"Diabetes Care"},{"key":"B3","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1097\/01.naj.0000490173.76651.27","article-title":"The FDA Revises Restrictions on Metformin Use in Kidney Impairment","volume":"116","author":"Aschenbrenner","year":"2016","journal-title":"Am. J. Nurs."},{"key":"B4","doi-asserted-by":"publisher","first-page":"128","DOI":"10.1186\/s12916-019-1351-4","article-title":"Tobacco Smoking and Risk of 36 Cardiovascular Disease Subtypes: Fatal and Non-fatal Outcomes in a Large Prospective Australian Study","volume":"17","author":"Banks","year":"2019","journal-title":"BMC Med."},{"key":"B5","doi-asserted-by":"publisher","first-page":"615","DOI":"10.1002\/pds.3424","article-title":"Does Antidepressant Medication Use Affect Persistence with Diabetes Medicines","volume":"22","author":"Caughey","year":"2013","journal-title":"Pharmacoepidemiol. Drug Saf."},{"key":"B6","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1016\/j.japh.2016.11.005","article-title":"Comparison of the Diabetes Guidelines from the ADA\/EASD and the AACE\/ACE","volume":"57","author":"Cornell","year":"2017","journal-title":"J. Am. Pharm. Assoc. (2003)"},{"key":"B7","doi-asserted-by":"publisher","first-page":"2096","DOI":"10.2337\/dc17-0662","article-title":"Time to Treatment Intensification after Monotherapy Failure and its Association with Subsequent Glycemic Control Among 93,515 Patients with Type 2 Diabetes","volume":"41","author":"Desai","year":"2018","journal-title":"Diabetes Care"},{"key":"B8","doi-asserted-by":"publisher","first-page":"2444","DOI":"10.1007\/s00125-014-3374-x","article-title":"Statins and Glycaemic Control in Individuals with Diabetes: a Systematic Review and Meta-Analysis","volume":"57","author":"Erqou","year":"2014","journal-title":"Diabetologia"},{"key":"B9","doi-asserted-by":"publisher","first-page":"1699","DOI":"10.1001\/archinte.168.15.1699","article-title":"The Hemoglobin A1C Level as a Progressive Risk Factor for Cardiovascular Death, Hospitalization for Heart Failure, or Death in Patients with Chronic Heart Failure: An Analysis of the Candesartan in Heart Failure: Assessment of Reduction in Mortality and Morbidity (CHARM) Program","volume":"168","author":"Gerstein","year":"2008","journal-title":"Arch. Intern. Med."},{"key":"B10","doi-asserted-by":"publisher","first-page":"947","DOI":"10.3390\/jcm9040947","article-title":"GLP-1 Receptor Agonists and Diabetic Kidney Disease: a Call of Attention to Nephrologists","volume":"9","author":"G\u00f3rriz","year":"2020","journal-title":"J. Clin. Med."},{"key":"B11","doi-asserted-by":"publisher","first-page":"1000","DOI":"10.1111\/bcp.12573","article-title":"Initial Therapy, Persistence and Regimen Change in a Cohort of Newly Treated Type 2 Diabetes Patients","volume":"79","author":"Grimes","year":"2015","journal-title":"Br. J. Clin. Pharmacol."},{"key":"B12","doi-asserted-by":"publisher","first-page":"E162","DOI":"10.9778\/cmajo.20130073","article-title":"Sulfonylurea versus Metformin Monotherapy in Patients with Type 2 Diabetes: a Cochrane Systematic Review and Meta-Analysis of Randomized Clinical Trials and Trial Sequential Analysis","volume":"2","author":"Hemmingsen","year":"2014","journal-title":"Can. Med. Assoc. J. open"},{"key":"B13","doi-asserted-by":"publisher","first-page":"1055","DOI":"10.1007\/s00125-018-4544-z","article-title":"Impact of Age at Diagnosis and Duration of Type 2 Diabetes on Mortality in Australia 1997-2011","volume":"61","author":"Huo","year":"2018","journal-title":"Diabetologia"},{"key":"B14","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1111\/dom.13088","article-title":"Therapeutic Inertia in the Treatment of Hyperglycaemia in Patients with Type 2 Diabetes: a Systematic Review","volume":"20","author":"Khunti","year":"2018","journal-title":"Diabetes Obes. Metab."},{"key":"B15","doi-asserted-by":"publisher","first-page":"300","DOI":"10.1053\/j.ajkd.2018.10.005","article-title":"Trends in Incidence of ESKD in People with Type 1 and Type 2 Diabetes in Australia, 2002-2013","volume":"73","author":"Koye","year":"2019","journal-title":"Am. J. Kidney Dis."},{"key":"B16","doi-asserted-by":"publisher","first-page":"493","DOI":"10.3390\/jcm7120493","article-title":"The Number of Comorbidities Predicts Renal Outcomes in Patients with Stage 3-5 Chronic Kidney Disease","volume":"7","author":"Lee","year":"2018","journal-title":"Jcm"},{"key":"B17","doi-asserted-by":"publisher","first-page":"423","DOI":"10.1016\/S2213-8587(15)00082-0","article-title":"The Association between Smoking Cessation and Glycaemic Control in Patients with Type 2 Diabetes: A THIN Database Cohort Study","volume":"3","author":"Lycett","year":"2015","journal-title":"Lancet Diabetes Endocrinol."},{"key":"B18","doi-asserted-by":"publisher","first-page":"349","DOI":"10.3389\/fpubh.2019.00349","article-title":"The Play of Genes and Non-genetic Factors on Type 2 Diabetes","volume":"7","author":"Mambiya","year":"2019","journal-title":"Front. Public Health"},{"key":"B19","doi-asserted-by":"publisher","first-page":"1735","DOI":"10.1007\/s12325-018-0819-5","article-title":"Addressing Clinical Inertia in Type 2 Diabetes Mellitus: A Review","volume":"35","author":"Okemah","year":"2018","journal-title":"Adv. Ther."},{"key":"B20","doi-asserted-by":"publisher","first-page":"e113","DOI":"10.2337\/dc18-0116","article-title":"Clinical Inertia in Type 2 Diabetes Management: Evidence from a Large, Real-World Data Set","volume":"41","author":"Pantalone","year":"2018","journal-title":"Diabetes Care"},{"key":"B21","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1186\/s12933-015-0260-x","article-title":"Delay in Treatment Intensification Increases the Risks of Cardiovascular Events in Patients with Type 2 Diabetes","volume":"14","author":"Paul","year":"2015","journal-title":"Cardiovasc. Diabetol."},{"key":"B22","doi-asserted-by":"publisher","first-page":"e021122","DOI":"10.1136\/bmjopen-2017-021122","article-title":"The Validity of the Rx-Risk Comorbidity index Using Medicines Mapped to the Anatomical Therapeutic Chemical (ATC) Classification System","volume":"8","author":"Pratt","year":"2018","journal-title":"BMJ Open"},{"key":"B23","doi-asserted-by":"publisher","first-page":"501","DOI":"10.1016\/j.diabet.2017.06.003","article-title":"Clinical Inertia and its Impact on Treatment Intensification in People with Type 2 Diabetes Mellitus","volume":"43","author":"Reach","year":"2017","journal-title":"Diabetes Metab."},{"first-page":"47","volume-title":"General Practice Management of Type 2 Diabetes \u2013 2014\u201315","year":"2014","key":"B24"},{"volume-title":"Management of Type 2 Diabetes: A Handbook for General Practice","year":"2020","key":"B25"},{"key":"B26","doi-asserted-by":"publisher","first-page":"840","DOI":"10.5114\/aoms.2015.53304","article-title":"Sulfonylureas and Their Use in Clinical Practice","volume":"11","author":"Sola","year":"2015","journal-title":"Arch. Med. Sci."},{"key":"B27","doi-asserted-by":"publisher","first-page":"1535","DOI":"10.1093\/eurheartj\/ehw039","article-title":"Treatment of Diabetes and Heart Failure: Joint Forces","volume":"37","author":"Swedberg","year":"2016","journal-title":"Eur. Heart J."},{"key":"B28","doi-asserted-by":"publisher","first-page":"1131","DOI":"10.1002\/pds.4020","article-title":"Statin Use and the Risk of Developing Diabetes: a Network Meta-Analysis","volume":"25","author":"Thakker","year":"2016","journal-title":"Pharmacoepidemiol. Drug Saf."},{"key":"B29","doi-asserted-by":"publisher","first-page":"e14024","DOI":"10.1371\/journal.pone.0014024","article-title":"Influence of Comorbidities on Therapeutic Progression of Diabetes Treatment in Australian Veterans: A Cohort Study","volume":"5","author":"Vitry","year":"2010","journal-title":"PLOS ONE"},{"key":"B30","doi-asserted-by":"publisher","first-page":"1367","DOI":"10.1111\/dme.14149","article-title":"Pharmacological Treatment Initiation for Type 2 Diabetes in Australia: Are the Guidelines Being Followed","volume":"37","author":"Wood","year":"2020","journal-title":"Diabet Med."},{"volume-title":"ATC: Structure and Principles","year":"2011","key":"B31"},{"key":"B32","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1111\/j.1463-1326.2011.01498.x","article-title":"Time to Treatment Initiation with Oral Antihyperglycaemic Therapy in US Patients with Newly Diagnosed Type 2 Diabetes","volume":"14","author":"Zhang","year":"2012","journal-title":"Diabetes Obes. Metab."}],"container-title":["Frontiers in Pharmacology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2021.794273\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,12,14]],"date-time":"2021-12-14T12:05:44Z","timestamp":1639483544000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2021.794273\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,12,14]]},"references-count":32,"alternative-id":["10.3389\/fphar.2021.794273"],"URL":"https:\/\/doi.org\/10.3389\/fphar.2021.794273","relation":{},"ISSN":["1663-9812"],"issn-type":[{"type":"electronic","value":"1663-9812"}],"subject":[],"published":{"date-parts":[[2021,12,14]]},"article-number":"794273"}}